Active specific immunotherapy for colorectal cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 5, 2003, Pages 685-694

  Indar, Adrian A ^a   Maxwell Armstrong, Charles A ^b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Anti idiotypic antibody; Colorectal cancer; Dendritic cells; Immunotherapy; Tumor escape

Indexed keywords

105AD 7; ANTIIDIOTYPIC ANTIBODY; B7 ANTIGEN; BCG VACCINE; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; CEAVAC; CYTOKINE; DECAY ACCELERATING FACTOR; DNA VACCINE; EDRECOLOMAB; FLUOROURACIL; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR1 ANTIGEN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; MUCIN 1; NAKED DNA; PLASMID VECTOR; RETROVIRUS VECTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DENDRITIC CELL; GENETIC MANIPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN ANALYSIS; REVIEW; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

EID: 0242350981     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.5.685     Document Type: Review

References (78)

1. Beart R. Colon and rectum. In: Clinical Oncology. Abeloff M (Ed.), Churchill Livingstone, NY, USA, 1267-1286 (1995).
2. Brodsky FM, Guagliardi LE. The cell biology of antigen processing and presentation. Ann. Rev. Immunol. 9, 707-744 (1991).
3. Geppert TD, Lipsky PE. Antigen presentation at the inflammatory site. Crit. Rev. Immunol. 9(4), 313-362 (1989).
4. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Ann. Rev. Immunol. 14, 207-232 (1996).
5. Nagata S. Apoptosis by death factor. Cell 88(3), 355-365 (1997).
6. Hoover HC Jr, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J. Clin. Oncol. 11(3), 390-399 (1993).
7. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of Stage II and Stage III colon cancer with an autologous tumor cell vaccine: first randomized Phase III trials show promise. Vaccine 19(17-19), 2576-2582 (2001).
8. Ockert D, Schirrmacher V, Beck N et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 2(1), 21-28 (1996).
9. Yannelli JR, Hyatt C, Johnson S, Hwu P, Rosenberg SA. Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor-α (TNF-α) or interleukin-2 (IL,2). J. Immunol. Methods 161(1), 77-90 (1993).
10. Fearon ER, Pardoll DM, Itaya T et al. Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response. Cell 60(3), 397-403 (1990).
11. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. USA 90(8), 3539-3543 (1993).
12. Chong H, Todryk S, Hutchinson G, Hart IR, Vile RG. Tumour cell expression of b7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther. 5(2), 223-232 (1998).
13. Colombo MP, Vagliani M, Spreafico F et al. Amount of interleukin-12 available at the tumor site is critical for tumor regression. Cancer Res. 56(11), 2531-2534 (1996).
14. Chen L, Linsley PS, Hellstrom KE. Costimulation of T-cells for tumor immunity. Immunol. Today 14(10), 483-486 (1993).
15. Vile RG, Castleden S, Marshall J et al. Generation of an antitumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer 71(2), 267-274 (1997).
16. Todryk SM, Chong H, Vile RG, Pandha H, Lemoine NR. Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut 43(4), 445-449 (1998).
17. Kubo RT, Sette A, Grey HM et al. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol. 152(8), 3913-3924 (1994).
18. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T-cells, b7 costimulation and T-helper cell 1-associated cytokines. J. Exp. Med. 183(1), 87-97 (1996).
19. Mukherji B, Chakraborty NG, Yamasaki S et al. Induction of antigen-specific cytolytic T-cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen-presenting cells. Proc. Natl. Acad. Sci. USA 92(17), 8078-8082 (1995).
20. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. 87(13), 982-990 (1995).
21. von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and b7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6(6), 2219-2228 (2000).
22. Hollingsworth MA, Strawhecker JM, Caffrey TC, Mack DR. Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int. J. Cancer 57(2), 198-203 (1994).
23. Apostolopoulos V, Osinski C, McKenzie IF. MUC1 cross-reactive gal α (1,3)gal antibodies in humans switch immune responses from cellular to humoral. Nature Med. 4(3), 315-320 (1998).
24. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63(1), 298-304 (1996).
25. Akagi J, Nakagawa K, Egami H, Ogawa M. Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T-lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus. Cancer Immunol. Immunother. 47(1), 21-31 (1998).
26. Saeki T, Salomon DS, Johnson GR et al. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn. J. Clin. Oncol. 25(6), 240-249 (1995).
27. Kapitanovic S, Radosevic S, Kapitanovic M et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112(4), 1103-1113 (1997).
28. Tanaka H, Tsunoda T, Nukaya I et al. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br. J. Cancer 84(1), 94-99 (2001).
29. Sasatomi T, Yamana H, Shichijo S et al. Expression of the SART1 tumor-rejection antigens in colorectal cancers. Dis. Colon Rectum 43(12), 1754-1758 (2000).
30. Lindemann J. Speculations on idiotypes and homobodies. Ann. Immunol. (Paris) 124(2), 171-184 (1973).
31. Jerne NK. Towards a network theory of the immune system. Ann. Immunol. (Paris) 125C(1-2), 373-389 (1974).
32. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T-cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function and responsiveness. Adv. Immunol. 27, 51-177 (1979).
33. Fagerberg J, Hjelm AL, Ragnhammar P et al. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T-lymphocytes. Cancer Res. 55(9), 1824-1827 (1995).
34. Herlyn D, Somasundaram R, Zaloudik J et al. Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer. Cell Biophys. 24-25, 143-153 (1994).
35. Staib L, Birebent B, Somasundaram R et al. Immunogenicity of recombinant ga733-2e antigen (co17-1a, egp, ks1-4, ksa, ep-cam) in gastro-intestinal carcinoma patients. Int. J. Cancer 92(1), 79-87 (2001).
36. Birebent B, Somasundaram R, Purev E et al. Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients. Crit. Rev. Oncol. Hematol. 39(1-2), 107-113 (2001).
37. Spendlove I, Li L, Carmichael J, Durrant LG. Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res. 59(10), 2282-2286 (1999).
38. Robins RA, Denton GW, Hardcastle JD et al. Antitumor immune response and interleukin-2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res. 51(19), 5425-5429 (1991).
39. Denton GW, Durrant LG, Hardcastle JD et al. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int. J. Cancer 57(1), 10-14 (1994).
40. Maxwell-Armstrong CA, Durrant LG, Buckley TJ et al. Randomized double-blind Phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105ad7 against placebo in advanced colorectal cancer. Br. J. Cancer 84(11), 1443-1446 (2001).
41. Maxwell-Armstrong CA, Durrant LG, Robins RA et al. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105ad7. Gut 45(4), 593-598 (1999).
42. Durrant LG, Maxwell-Armstrong C, Buckley D et al. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105ad7, which mimics CD55. Clin. Cancer Res. 6(2), 422-430 (2000).
43. Durrant LG, Buckley DJ, Robins RA, Spendlove I. 105ad7 cancer vaccine stimulates antitumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int. J. Cancer 85(1), 87-92 (2000).
44. Amin S, Robins RA, Maxwell-Armstrong CA, Scholefield JH, Durrant LG. Vaccine-induced apoptosis: a novel clinical trial end point? Cancer Res. 60(12), 3132-3136 (2000).
45. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M et al. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res. 57(4), 728-734 (1997).
46. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin. Cancer Res. 3(8), 1267-1276 (1997).
47. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. 17(9), 2889-2885 (1999).
48. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998).
49. Satthaporn S, Eremin O. Dendritic cells (I): biological functions. J. R. Coll. Surg. Edinb. 46(1), 9-19 (2001).
50. Brossart P, Stuhler G, Flad T et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T-lymphocytes. Cancer Res. 58(4), 732-736 (1998).
51. Navabi H, Jasani B, Adams M et al. Generation of in vitro autologous human cytotoxic T-cell response to E7 and Her-2/neu oncogene products using ex vivo peptide loaded dendritic cells. Adv. Exp. Med. Biol. 417, 583-589 (1997).
52. Brossart P, Heinrich KS, Stuhler G et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93(12), 4309-44317 (1999).
53. van der Bruggen P, Szikora JP, Boel P et al. Autologous cytolytic T-lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-cw* 1601. Eur. J. Immunol. 24(9), 2134-2140 (1994).
54. Wolfel T, van Pel A, Brichard V et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T-lymphocytes. Eur. J. Immunol. 24(3), 759-764 (1994).
55. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193(2), 233-238 (2001).
56. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin-10-producing, nonproliferating CD4(+) T-cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192(9), 1213-1222 (2000).
57. Oliveira SC, Rosinha GM, de-Brito CF et al. Immunological properties of gene vaccines delivered by different routes. Braz. J. Med. Biol. Res. 32(2), 207-214 (1999).
58. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1(12), 1297-1302 (1995).
59. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 48(38), 347-351 (2001).
60. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4(3), 328-332 (1998).
61. Morse MA, Nair S, Fernandez-Casal M et al. Preoperative mobilization of circulating dendritic cells by flt3 ligand administration to patients with metastatic colon cancer. J. Clin. Oncol. 18(23), 3883-3893 (2000).
62. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with flt3 ligand expanded dendritic cells for tumor immunotherapy Proc. Natl. Acad. Sci. USA 98(15), 8809-8814 (2001).
63. Avery A, Paraskeva C, Hall P et al. TGF-β expression in the human colon: differential immunostaining along crypt epithelium. Br. J. Cancer 68(1), 137-139 (1993).
64. Gastl GA, Abrams JS, Nanus DM et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer 55(1), 96-101 (1993).
65. Pellegrini P, Berghella AM, Del Beato T et al. Disregulation in Th1 and Th2 subsets of CD4+ T-cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol. Immunother. 42(1), 1-8 (1996).
66. Qin Z, Richter G, Schuler T et al. B-cells inhibit induction of T-cell-dependent tumor immunity. Nature Med. 4(5), 627-630 (1998).
67. Wigmore SJ, Maingay JP, Fearon KC, Ross JA. Endogenous production of IL-8 by human colorectal cancer cells and its regulation by cytokines. Int. J. Oncol. 18(3), 467-473 (2001).
68. Peoples GE, Blotnick S, Takahashi K et al. T-lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc. Natl Acad. Sci. USA 92(14), 6547-6551 (1995).
69. Freeman MR, Schneck FX, Gagnon ML et al. Peripheral blood T-lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T-cells in angiogenesis. Cancer Res. 55(18), 4140-4145 (1995).
70. Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible b7 expression in rats. Int. J. Cancer 72(4), 619-624 (1997).
71. Kuppen PJ, van der Eb MM, Jonges LE et al. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem. Cell Biol. 115(1), 67-72 (2001).
72. Kruger K, Buning C, Schriever F. Activated T-lymphocytes bind in situ to stromal tissue of colon carcinoma but lack adhesion to tumor cells. Eur. J. Immunol. 31(1), 138-145 (2001).
73. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br. J. Cancer 82(5), 1009-1012 (2000).
74. Matsuda M, Petersson M, Lenkei R et al. Alterations in the signal-transducing molecules of T-cell and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer 61(6), 765-772 (1995).
75. Nakagomi H, Petersson M, Magnusson I et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53(23), 5610-5612 (1993).
76. Powell SM, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigenesis. Nature 359(6392), 235-237 (1992).
77. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184(3), 1075-1082 (1996).
78. Rivoltini L, Radrizzani M, Accornero P et al. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J. Immunol. 161(3), 1220-1230 (1998).